These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

399 related items for PubMed ID: 33812141

  • 1. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group.
    Grimmelmann I, Momma M, Zimmer L, Hassel JC, Heinzerling L, Pföhler C, Loquai C, Ruini C, Utikal J, Thoms KM, Kähler KC, Eigentler T, Herbst RA, Meier F, Debus D, Berking C, Kochanek C, Ugurel S, Gutzmer R, German Dermatooncology Group (DeCOG).
    Eur J Cancer; 2021 May; 149():1-10. PubMed ID: 33812141
    [Abstract] [Full Text] [Related]

  • 2. Coexistence of Immune Checkpoint Inhibitor-Induced Autoimmune Diabetes and Pancreatitis.
    Zhang AL, Wang F, Chang LS, McDonnell ME, Min L.
    Front Endocrinol (Lausanne); 2021 May; 12():620522. PubMed ID: 33927691
    [Abstract] [Full Text] [Related]

  • 3. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury.
    Abu-Sbeih H, Tang T, Lu Y, Thirumurthi S, Altan M, Jazaeri AA, Dadu R, Coronel E, Wang Y.
    J Immunother Cancer; 2019 Feb 06; 7(1):31. PubMed ID: 30728076
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pancreatic adverse events of immune checkpoint inhibitors therapy for solid cancer patients: a systematic review and meta-analysis.
    Zhao Z, Zhang W, Pang L, Zeng L, Liu S, Liu J.
    Front Immunol; 2023 Feb 06; 14():1166299. PubMed ID: 37359551
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports.
    Zezza M, Kosinski C, Mekoguem C, Marino L, Chtioui H, Pitteloud N, Lamine F.
    BMC Endocr Disord; 2019 Dec 23; 19(1):144. PubMed ID: 31870373
    [Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus.
    Hilder R, Tsai K, Quandt Z, Isaacs D, Drakaki A, Xing Y, In GK, Angell TE, Lechner MG.
    Front Endocrinol (Lausanne); 2023 Dec 23; 14():1242830. PubMed ID: 38027216
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL, Jaggi S, Sirisena I, Sharda P, Rao AD, Mehra R, Veloski C.
    J Immunother Cancer; 2017 Dec 23; 5():40. PubMed ID: 28515940
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Type 3 autoimmune pancreatitis (immune checkpoint inhibitor-induced pancreatitis).
    Sayed Ahmed A, Abreo M, Thomas A, Chari ST.
    Curr Opin Gastroenterol; 2022 Sep 01; 38(5):516-520. PubMed ID: 35881977
    [Abstract] [Full Text] [Related]

  • 13. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.
    Li M, Sack JS, Rahma OE, Hodi FS, Zucker SD, Grover S.
    Cancer; 2020 Dec 01; 126(23):5088-5097. PubMed ID: 32888341
    [Abstract] [Full Text] [Related]

  • 14. Increased risk of immune checkpoint inhibitor-induced type 1 diabetes mellitus with the new approved 6-week scheme of pembrolizumab in patients with melanoma?
    Kähler KC, Kosova K, Bohne AS, Schreiber S, Hauschild A.
    Eur J Cancer; 2020 Oct 01; 138():169-171. PubMed ID: 32890812
    [No Abstract] [Full Text] [Related]

  • 15. Pancreatic involvement due to immune checkpoint inhibitors: a proposed classification.
    Ashkar M, Chandra S, Vege SS, Takahashi H, Takahashi N, McWilliams RR.
    Cancer Immunol Immunother; 2023 Apr 01; 72(4):895-901. PubMed ID: 36161510
    [Abstract] [Full Text] [Related]

  • 16. Predictors of the Onset of Type 1 Diabetes Obtained from Real-World Data Analysis in Cancer Patients Treated with Immune Checkpoint Inhibitors.
    Takada S, Hirokazu H, Yamagishi K, Hideki S, Masayuki E.
    Asian Pac J Cancer Prev; 2020 Jun 01; 21(6):1697-1699. PubMed ID: 32592366
    [Abstract] [Full Text] [Related]

  • 17. Type 1 diabetes associated with immune checkpoint inhibitors for malignant melanoma: A case report and review of 8 cases.
    Ishiguro A, Ogata D, Ohashi K, Hiki K, Yamakawa K, Jinnai S, Tsutsui K, Takahashi A, Namikawa K, Yamazaki N.
    Medicine (Baltimore); 2022 Sep 02; 101(35):e30398. PubMed ID: 36107581
    [Abstract] [Full Text] [Related]

  • 18. Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus Is Characterized by C-peptide Loss and Pancreatic Atrophy.
    Wu L, Carlino MS, Brown DA, Long GV, Clifton-Bligh R, Mellor R, Moore K, Sasson SC, Menzies AM, Tsang V, Gunton JE.
    J Clin Endocrinol Metab; 2024 Apr 19; 109(5):1301-1307. PubMed ID: 37997380
    [Abstract] [Full Text] [Related]

  • 19. Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy.
    Dimitriou F, Hogan S, Menzies AM, Dummer R, Long GV.
    Eur J Cancer; 2021 Nov 19; 157():214-224. PubMed ID: 34536945
    [Abstract] [Full Text] [Related]

  • 20. A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome.
    Marsiglio J, McPherson JP, Kovacsovics-Bankowski M, Jeter J, Vaklavas C, Swami U, Grossmann D, Erickson-Wayman A, Soares HP, Kerrigan K, Gibson B, Doherty JA, Hyngstrom J, Hardikar S, Hu-Lieskovan S.
    Front Immunol; 2023 Nov 19; 14():1229823. PubMed ID: 37671166
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.